Profile data is unavailable for this security.
About the company
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
- Revenue in USD (TTM)133.62m
- Net income in USD-177.37m
- Incorporated2004
- Employees280.00
- LocationXencor Inc465 N. HALSTEAD ST., SUITE 200PASADENA 91107United StatesUSA
- Phone+1 (626) 305-5900
- Fax+1 (626) 305-0350
- Websitehttps://xencor.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day One Biopharmaceuticals Inc | 8.19m | -167.48m | 1.30bn | 169.00 | -- | 4.23 | -- | 158.34 | -1.94 | -1.94 | 0.0948 | 3.50 | 0.0193 | -- | -- | 52,851.61 | -39.35 | -- | -45.70 | -- | 91.37 | -- | -2,044.43 | -- | 4.09 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Gyre Therapeutics Inc | 165.85m | -79.66m | 1.31bn | 593.00 | -- | 19.89 | -- | 7.90 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.32bn | 50.00 | -- | 4.47 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Cassava Sciences Inc | 0.00 | -15.37m | 1.43bn | 29.00 | -- | 7.56 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Disc Medicine Inc | 0.00 | -91.00m | 1.43bn | 74.00 | -- | 2.92 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.43bn | 23.00 | -- | 6.65 | -- | 2,863.66 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Ardelyx Inc | 210.00m | -65.15m | 1.44bn | 267.00 | -- | 9.82 | -- | 6.87 | -0.2788 | -0.2788 | 0.9052 | 0.6244 | 0.7572 | 2.74 | 9.06 | 786,513.10 | -23.49 | -46.14 | -30.26 | -57.32 | 86.03 | 88.15 | -31.02 | -240.87 | 3.99 | -6.91 | 0.4055 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Xencor Inc | 133.62m | -177.37m | 1.47bn | 280.00 | -- | 2.31 | -- | 11.02 | -2.90 | -2.90 | 2.19 | 9.14 | 0.1666 | -- | 6.35 | 477,207.20 | -22.40 | -3.70 | -24.25 | -4.12 | -- | -- | -134.45 | -15.92 | -- | -- | 0.0331 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Belite Bio Inc (ADR) | 0.00 | -35.29m | 1.48bn | 20.00 | -- | 12.94 | -- | -- | -1.23 | -1.23 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -39.40 | -- | -39.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Dynavax Technologies Corp | 249.70m | 17.18m | 1.49bn | 408.00 | 112.25 | 2.31 | 68.65 | 5.96 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Arcus Biosciences Inc | 247.00m | -249.00m | 1.51bn | 577.00 | -- | 2.37 | -- | 6.10 | -3.10 | -3.10 | 3.02 | 6.96 | 0.2053 | -- | 7.06 | 428,076.30 | -20.70 | -15.85 | -24.57 | -18.25 | -- | -- | -100.81 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Spyre Therapeutics Inc | 0.00 | -185.98m | 1.53bn | 50.00 | -- | 7.01 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 3.50m | -264.08m | 1.55bn | 112.00 | -- | 3.58 | -- | 444.20 | -3.38 | -3.38 | 0.0447 | 5.11 | 0.0077 | -- | 0.6132 | 31,250.00 | -58.15 | -27.90 | -63.20 | -30.15 | -- | -- | -7,545.20 | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
CareDx Inc | 297.08m | -159.64m | 1.56bn | 635.00 | -- | 5.89 | -- | 5.26 | -2.99 | -2.99 | 5.62 | 5.03 | 0.6053 | 5.46 | 5.04 | 467,848.80 | -32.53 | -17.54 | -38.52 | -20.85 | 64.98 | 65.50 | -53.73 | -27.78 | 3.85 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
Kura Oncology Inc | 0.00 | -181.75m | 1.61bn | 142.00 | -- | 3.44 | -- | -- | -2.23 | -2.23 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -36.00 | -26.04 | -38.16 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0198 | -- | -- | -- | -12.36 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 9.85m | 15.97% |
PRIMECAP Management Co.as of 30 Jun 2024 | 9.12m | 14.78% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.88m | 11.15% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 5.33m | 8.64% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.24m | 6.87% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.69m | 5.99% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.44m | 2.33% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.34m | 2.17% |
Darwin Global Management Ltd.as of 31 Mar 2024 | 1.11m | 1.80% |
Armistice Capital LLCas of 31 Mar 2024 | 1.00m | 1.62% |